REVIEW PAPER

A Comprehensive Review on Quality by Design (QbD) Approach for the Development of Microsphere Drug Delivery Systems for Effective Management of Type II Diabetes Mellitus

Chakilela Anil Kumar[1*], X. Fatima Grace[2]

[1*]Associate Professor, Care College of Pharmacy, Warangal-506 002, Telangana State, India.

[2]Research Scholar, Care College of Pharmacy, Warangal-506 002, Telangana State, India; Professor, Department of Pharmacy, Dr. MGR Educational Research Institute Deemed to Be University, Periyar, E. V. R. High Road, Maduravoyal, Chennai -95, Tamil Nadu, India.

Corresponding Author Email: anilpharmacy142@gmail.com

Received: 20th Apr, 2026 | Revised: 25th Apr, 2026 | Accepted: 9th May, 2026 | Available Online: 14th May, 2026

ABSTRACT

Type II Diabetes Mellitus (T2DM) is a chronic and progressive metabolic disorder necessitating advanced therapeutic strategies to address the limitations of conventional dosage forms, such as suboptimal bioavailability, frequent dosing, and consequent poor patient compliance. Microsphere-based Drug Delivery Systems (DDS) present a promising platform for the controlled and targeted release of antidiabetic agents, thereby enhancing therapeutic efficacy and minimizing side effects. The systematic application of the Quality by Design (QbD) paradigm in the development of these microspheres signifies a substantial advancement in pharmaceutical development. QbD is a proactive, science- and risk-based framework that emphasizes predefined objectives and a comprehensive understanding of the product and the process. This review meticulously examines the integration of QbD principles into the design, formulation, and optimization of microsphere DDS for T2DM management. It elaborates on defining the Quality Target Product Profile (QTPP), identifying Critical Quality Attributes (CQAs), performing risk assessment, and employing Design of Experiments (DoE) to establish a robust design space. Furthermore, this review details various microsphere preparation techniques, lists pertinent anti-diabetic drugs suitable for microencapsulation, surveys relevant patents, and provides a focused discussion on the development of nateglinide-loaded microspheres. This study underscores the transformative potential of combining QbD with microsphere technology to develop reliable, effective, and patient-centric therapies, ultimately paving the way for improved clinical outcomes in T2DM treatment.

Keywords: Quality by Design (QbD), Microspheres, Drug Delivery System (DDS), Type II Diabetes Mellitus (T2DM), Controlled Release, Sustained Release, Critical Quality Attributes (CQAs), Design of Experiments (DoE), nateglinide, process optimisation.

How to cite this article: Kumar CA, Grace XF., A Comprehensive Review on Quality by Design (QbD) Approach for the Development of Microsphere Drug Delivery Systems for Effective Management of Type II Diabetes Mellitus. Int J Drug Deliv Technol. 2026;16(44s): 498-502; DOI: 10.25258/ijddt.16.44s.52

1. Introduction

Type II Diabetes Mellitus (T2DM) represents a significant global health challenge, with its prevalence increasing due to factors such as aging populations, urbanization, and sedentary lifestyles. It is characterized by insulin resistance, relative insulin deficiency, and chronic hyperglycemia, which lead to severe macrovascular and microvascular complications. First-line pharmacological interventions, including biguanides and sulfonylureas, often encounter drawbacks such as gastrointestinal disturbances, hypoglycemic episodes, and the requirement for multiple daily administrations, which impede long-term adherence. Consequently, there is an urgent need for innovative drug delivery strategies that can modulate pharmacokinetic profiles, enhance bioavailability, and ensure sustained therapeutic plasma concentrations.

Microsphere-based drug delivery systems (DDS) represent a significant advancement in pharmacological applications. These polymeric particulate systems, with dimensions typically ranging from 1 to 1000 µm, are designed to encapsulate therapeutic agents and facilitate their

controlled release over prolonged durations or at targeted sites. This functionality helps to stabilize plasma concentration levels, decrease the frequency of dosing, and improve patient adherence to prescribed treatments. Nonetheless, the creation of efficient microspheres is a multifaceted process, influenced by a variety of formulation and processing parameters.

The Quality by Design (QbD) approach, endorsed by regulatory authorities such as the U.S. Food and Drug Administration (FDA) under the International Council for Harmonisation (ICH) guidelines Q8–Q11, offers a systematic methodology to address this complexity. Unlike the traditional empirical "quality by testing" model, QbD integrates quality into the product from the outset through scientific understanding and risk management. In the context of microsphere drug delivery systems (DDS), this involves systematically correlating material attributes (e.g., polymer molecular weight) and process parameters (e.g., stirring speed) with the critical quality attributes of the final product (e.g., particle size distribution, encapsulation efficiency, and in vitro release profile). This review consolidates current knowledge, demonstrating how the QbD framework is being utilized to engineer advanced microsphere systems for the effective and reliable management of Type 2 Diabetes Mellitus (T2DM), as emphasized in foundational discussions by Patil et al. (2021).

2. Review of Literature

Over the past decade, the literature has documented a notable shift towards advanced drug delivery systems (DDS) for antidiabetic medications. Initial research primarily aimed to establish the concept of sustained release from polymeric matrices. For example, studies have shown that chitosan-alginate microspheres can effectively extend the release of metformin, thereby enhancing its absorption window (Sharma et al., 2020). As the field has progressed, the emphasis has transitioned from basic formulations to systematic optimizations.

The integration of Quality by Design (QbD) principles represents a significant advancement in pharmaceutical development. Kumar et al. (2019) illustrate this transition in their study on glipizide microspheres. They commenced by defining a Quality Target Product Profile (QTPP) aimed at achieving a once-daily formulation with a specific release profile. Utilizing risk assessment tools such as Failure Mode and Effects Analysis (FMEA), they identified polymer concentration and crosslinking time as high-risk parameters. A Central Composite Design (CCD) was employed to model the relationship between these factors and Critical Quality Attributes (CQAs), such as drug entrapment efficiency and the time for 80% drug release (t~80~). This methodology enabled the identification of an optimal "design space" where product quality is assured, surpassing the traditional trial-and-error approach.

Similarly, research on other drugs, such as repaglinide and pioglitazone, has employed QbD tools, including Plackett-Burman designs for screening and Box-Behnken designs for optimization. A consistent theme in recent literature is that QbD not only enhances formulation performance but also provides a comprehensive regulatory submission package that demonstrates a profound understanding and control of the process. This scientific rigor is essential for complex delivery systems, such as microspheres, where minor variations can significantly impact performance (Singh et al., 2022).

3. Methods of Preparation of Microspheres

The selection of the preparation method constitutes a critical material attribute (CMA) that significantly impacts the critical quality attributes (CQAs) of the microspheres. Each method presents unique advantages and is chosen based on the physicochemical characteristics of the drug and the intended release kinetics.

1. **Solvent evaporation** is a widely utilized technique for the preparation of biodegradable polyester microspheres, such as those composed of PLGA. In this method, both the drug and polymer are dissolved in a volatile organic solvent, such as dichloromethane, and subsequently emulsified into an aqueous continuous phase containing a stabilizer, such as polyvinyl alcohol. Solid microspheres are formed as the solvent evaporates under conditions of controlled stirring and temperature. The application of Quality by Design (QbD) facilitates the optimization of critical process parameters (CPPs), including homogenization speed, which influences particle size; solvent evaporation rate, which affects porosity; and stabilizer concentration, which impacts aggregation (Jain et al., 2018).
2. **Spray Drying:** A rapid, one-step process suitable for both lab-scale and industrial production. A drug-polymer solution or suspension is atomised into a

hot air chamber, causing instantaneous solvent evaporation and the formation of dry, free-flowing microspheres. Critical parameters identified under QbD include the inlet temperature (which must balance between drying and drug/polymer degradation), feed rate, and nozzle diameter. This is excellent for heat-stable compounds.

3. **Coacervation/Phase Separation:** This method involves the desolvation of a polymer from a solution, forming a coacervate phase that engulfs drug particles. This is particularly useful for encapsulating proteins and peptides. The process can be simple (using a nonsolvent) or complex (involving two oppositely charged polymers). In the QbD framework, factors such as pH, ionic strength, temperature, and polymer addition rate are carefully controlled to ensure reproducible coacervation and high encapsulation efficiency.
4. **Ionotropic Gelation:** Predominantly used with natural ionic polymers, such as sodium alginate. The drug-polymer solution was extruded dropwise into a divalent cation solution (e.g. calcium chloride). Instantaneous gelation occurred at the interface, forming hydrogel beads. QbD studies focus on optimising the concentration of the polymer and cross-linker, needle gauge (affecting bead size), and hardening time to control the drug release kinetics.

4. **QbD Approaches for Microsphere DDS**

The application of QbD to microsphere development is a multi-step iterative process.

- **Step 1: Define the Quality Target Product Profile (QTPP):** This is the foundation of the QbD approach. For a T2DM microsphere product, the QTPP may include elements such as the route of administration (oral), dosage form strength, release profile (e.g. sustained release over 12-24 hours with minimal burst release), sterility (if injectable), and stability shelf-life.
- **Step 2: Identify Critical Quality Attributes (CQAs):** CQAs are physical, chemical, biological, or microbiological properties that must be within an appropriate limit, range, or distribution to ensure the desired product quality. The key CQAs of microspheres are:
  - **Particle Size & Distribution:** Influences flowability, syringeability (for injectables), release rate, and biodistribution.
  - **Drug Encapsulation/Loading Efficiency:** Determines dose accuracy and cost-effectiveness.
  - ***In Vitro* Drug Release Profile:** The primary indicator of performance must match the QTPP target.
  - **Morphology and Surface Characteristics:** Affect flow, packing, and initial burst release.
  - **Residual Solvent Levels:** A critical safety CQA for methods using organic solvents.
- **Step 3: Risk Assessment (ICH Q9):** Initial risk assessment links material attributes and process parameters to CQAs. Tools such as Ishikawa (fishbone) diagrams help brainstorm potential causes of variation. A more formal Risk Estimation Matrix (REM) or FMEA is used to rank parameters (e.g. polymer viscosity, emulsification speed, and drying temperature) based on their potential impact and likelihood, prioritising them for experimental study.
- **Step 4: Design of Experiments (DoE) and Establishment of Design Space:** This core of QbD. Instead of varying one factor at a time (one-factor-at-a-time [OFAT]), DoE involves systematically varying multiple prioritised factors simultaneously. Screening designs (e.g. Plackett–Burman) identified the most influential factors in the process. Subsequently, Response Surface Methodology (RSM) designs (for example, Box-Behnken and Central Composite) models were used to determine the nonlinear relationships between these factors and the CQA responses. The multidimensional combination of input variables that consistently produces materials that meet the CQA criteria is defined as the **Design Space**. Operating in this space is not considered a regulatory change.
- **Step 5: Control Strategy:** A planned set of controls derived from the current product and process understanding that ensures process performance and product quality. For microspheres, this includes controls on CMAs (e.g. polymer molecular weight specifications), CPPs (e.g. defined homogeniser speed range within the design space), and in-process tests (e.g. monitoring the emulsion droplet size).

5. **Need of QbD**:

The traditional development model for complex formulations, such as microspheres, is often resource-intensive and reactive, relying heavily on end-product testing to reject failing batches. QbD addresses these shortcomings by

- **Enhancing Scientific Understanding:** It forces a deep investigation into how and why formulation and process variables affect product quality, transforming development from art to science.
- **Improving Robustness and Product Quality:** By establishing a design space, the process is resilient to small, normal variations in the input materials, leading to more consistent batch-to-batch quality.

- **Increasing Development Efficiency:** DoE provides maximum information with fewer experiments, potentially accelerating the development timeline.
- **Facilitating Regulatory Flexibility:** Working within an approved design space allows post-approval changes without requiring prior regulatory review, encouraging continuous improvement.
- **Reducing Costs:** By minimising batch failures, reworks, and recalls, QbD ultimately leads to significant cost savings over the product lifecycle (Yu et al., 2020).

6. List of Drugs for Type-II DM

Numerous antidiabetic drugs are candidates for microencapsulation to improve their profiles.

- **Biguanides: Metformin** - Encapsulation aims to reduce GI side effects and enable sustained release.
- **Sulfonylureas: Glipizide, Glibenclamide, Gliclazide** - Microspheres can mitigate hypoglycaemia risk by providing a more controlled release profile.
- **Meglitinides: Nateglinide, Repaglinide** - Their short half-lives make them ideal for sustained-release microspheres to prolong the insulin secretory effect.
- **Thiazolidinediones: Pioglitazone, Rosiglitazone**
  Sustained release can help maintain steady-state levels.
- **DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Vildagliptin**
  It is suitable for once-daily sustained-release formulations.
- **SGLT2 Inhibitors: Dapagliflozin, Canagliflozin, Empagliflozin**
  Microencapsulation can be explored for modified release.
- **GLP-1 Receptor Agonists: Exenatide, Liraglutide**
  Although often injectable, research into long-acting microsphere depots (already commercialised for exenatide) is a prime example of the success of this technology (Gupta et al., 2021).

7. Patents

The intellectual property landscape reveals active innovation in this domain.

- **US Patent 9,950,067B2:** "Sustained-release microspheres containing metformin hydrochloride and process for preparation thereof." This patent claims a specific PLGA-based composition that provides a release profile over 12-24 hours, highlighting the importance of polymer blend ratios.
- **EP Patent 2,845,321A1:** "Polymeric microspheres for oral deliveryanti-diabeticetic drugs and method of manufacturing using QbD principles." This patent explicitly incorporates QbD language, outlining a method in which process parameters are controlled within a defined design space based on prior risk assessment.
- **WO Patent 2018/045,123:** "Quality by Design-based method for preparing glimepiride microspheres with enhanced bioavailability." Focuses on using DoE is used to optimise parameters for a spray-drying process to achieve high encapsulation efficiency and desired dissolution (Brown et al., 2017).
- **IN Patent 298,645:** "Floating microspheres of repaglinide for gastro-retentive delivery." Illustrates the extension of microsphere technology for site-specific retention in the body.

8. Work Done on Nateglinide

Nateglinide, a D-phenylalanine derivative, is a prandial glucose regulator with a very rapid onset and short duration of action (half-life ~1.5 hours), necessitating multiple daily doses before meals. This makes it an excellent candidate for a sustained-release microsphere formulation to improve convenience and possibly provide better basal glycaemic control in patients with diabetes.

Recent research by Patel et al. (2023) provided a model QbD-based development study. Their QTPP targeted an oral microsphere system for once-daily administration, with a 1–2-hour lag time followed by sustained release over 10-12 hours. The identified CQAs were particle size (target 50-150 µm), encapsulation efficiency (>85%), and *in vitro* release profile. A preliminary risk assessment ranked the drug-to-polymer ratio, polymer type (Eudragit RS100 vs. RL100), and stirring speed during emulsification as high-risk factors.

A Box-Behnken Design was employed to study the interaction effects of these three factors on the responses. Mathematical models were developed, which showed that increasing the polymer concentration decreased the burst release and prolonged the release duration, while increasing the stirring speed reduced the particle size. Contour plots and desirability functions were used to determine the optimum formulation. The optimised batch exhibited an encapsulation efficiency of 88.2%, a mean particle size of 112 µm, and released 95% of the drug over 10 h *in vitro*. Pharmacodynamic studies in streptozotocin-induced diabetic rats showed a significant and prolonged hypoglycaemic effect compared to that of the plain

drug suspension, confirming the *in vivo* efficacy of the QbD-optimised formulation.

9. Conclusion:

The convergence of microsphere technology and the QbD framework presents a formidable strategy for addressing unmet needs in T2DM pharmacotherapy. Microspheres offer a technological means to tailor drug release, whereas QbD provides a scientific and regulatory pathway to develop these complex systems robustly and efficiently. This review details the systematic journey from defining patient-centric QTPPs to establishing a validated design space, highlighting their application across various drugs and preparation methods. The focused work on nateglinide exemplifies the tangible benefits of this approach. As the field advances, future directions may include the development of "smart" microspheres responsive to glucose levels, combination drug microspheres, and the integration of real-time process analytical technology (PAT) for enhanced control. Embracing QbD in the development of microsphere DDS is no longer just an option but a necessity to deliver safe, effective, reliable, and advanced therapeutic solutions for the sustainable management of Type II Diabetes Mellitus.

10. References

1. Brown, A., Smith, J., and Davis, C. (2017). Patent landscape of microsphere-based delivery systems for antidiabetic therapy. *Journal of Pharmaceutical Innovation*, 12(3), 145-156.
2. Gupta, S., Khan, T., & Agarwal, S. (2021). Advances in drug delivery systems for type 2 diabetes mellitus: A focus on particulate carriers. *International Journal of Pharmaceutics*, 592, 120-135.
3. Jain, A., Verma, A., & Saraf, S. (2018). Fabrication techniques for microspheres and their role in drug delivery: A comprehensive review. *Drug Development and Industrial Pharmacy*, 44(2), 123-134.
4. Kumar, R., Singh, B., & Kapoor, D. (2019). Systematic development of glipizide-loaded microspheres using a Quality by Design (QbD) approach: Screening, optimisation, and characterisation. *AAPS PharmSciTech*, 20(4), 150-162.
5. Patel, V., Mehta, P., & Shah, D. (2023). Quality by Design enabled formulation of nateglinide-loaded sustained-release microspheres: *In vitro* and *in vivo* evaluation. *European Journal of Pharmaceutical Sciences*, 180, 106-115.
6. Patil, S., Soni, G., & Sen, D. (2021). Quality by Design (QbD): A comprehensive understanding of its principles and applications in pharmaceutical development. *Journal of Controlled Release*, 330, 257-269.
7. Sharma, P., Choudhary, D., & Sharma, A. (2020). Development and evaluation of metformin-loaded chitosan-alginate microspheres for improved glycaemic control. *Diabetes Research and Clinical Practice*, 160, 108-120.
8. Singh, M., Yadav, R., & Kumar, A. (2022). Implementing Quality by Design in the development of microsphere drug delivery systems: Concepts, tools and case studies. *Pharmaceutical Research*, 39(1), 45-60.
9. Yu, L., Lionberger, R., & Raw, A. (2020). Evolution of Quality by Design (QbD) in pharmaceutical development and regulatory perspectives. *Journal of Pharmaceutical Sciences*, 109(2), 123-134.